在雷诺现象中增强胆能皮肤血管扩张
1Peripheral Vascular Section, Evans Memorial Department of Clinical Research, Boston University Medical Center, MA.
Circulation
|March 1, 1994
概括
患有雷诺现象的患者表现出指尖和前臂皮肤对甲醇的血管扩展反应增强,这表明皮肤血管反应增加. 这可能与雷诺现象中血管的病理生理学有关.
科学领域:
- 血管生理学 血管生理学
- 皮肤病学 皮肤病学
- 心血管研究的心血管研究.
背景情况:
- 雷诺氏现象的特点是过度的血管收缩.
- 了解血管扩张器的功能对于管理这种情况至关重要.
- 对内皮依赖和独立的血管扩张器是评估血管功能的关键.
研究的目的:
- 为了确定雷诺现象患者的血管扩张功能.
- 为了比较对依赖内皮质 (甲醇) 和不依赖内皮质 (酸) 的血管扩展剂的反应.
- 为了研究雷诺现象患者的反应性高血压.
主要方法:
- 在动脉内注入甲醇和酸的输液.
- 静脉闭塞复合图用于指尖和前臂的血液流动.
- 激光多普勒流量计用于前臂皮肤的血液流动.
- 在动脉封闭后测量反应性高血压.
主要成果:
- 患有雷诺现象的患者显示,与对照组不同,用甲索林的指尖血流显著增加,与对照组不同.
- 前臂皮肤的血流在雷诺病患者中表现出对甲索林的更强的血管扩张反应.
- 总前臂血流和反应性高血压反应在两组血管扩张剂之间是相似的.
结论:
- 雷诺氏现象与指尖和前臂皮肤中血管扩展反应的增强有关.
- 这表明皮肤血管对雷诺氏症内皮质刺激的反应性增加.
- 潜在的机制可能涉及与血管有关的皮肤血管的普遍异常.
相关概念视频
Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cholinergic Antagonists: Pharmacological Actions
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...


